

ABSTRACT

Provided is a method for treating chronic-phase and/or accelerated-phase and/or blast-phase chronic myelogenous leukemia and/or acute lymphoblastic leukemia in a subject by administering to the subject a compound of formula (I) or a pharmaceutically acceptable salt, crystal form, solvate or hydrate thereof. Also provided is a use of the compound of formula (I) or the pharmaceutically acceptable salt, crystal form, solvate or hydrate thereof in combination with an ATP-competitive BCR-ABL1 inhibitor.

